Clinical results of Vaxxas needle free vaccine technology

Vaxxas announced positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using its proprietary high-density microarray patch (HD-MAP) technology.   The COVID-19 vaccine involves HD-MAP delivery of HexaPro, a second-generation version of the spike protein used in all major U.S. approved COVID-19 vaccines, which was modified […]